Education
About Us
Working with TipRanks
Follow Us
Curis Inc (CRIS)
NASDAQ:CRIS
Earnings Data
Report Date
May 12, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.29Last Year’s EPS
-1.25Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call contained several meaningful clinical and financial positives: a clear registrational pathway and regulatory alignment for PCNSL, encouraging AML MRD conversion data (62.5% in evaluable patients), initiation of a CLL proof-of-concept study with expected ASH data, and sharply reduced operating expenses with an improved full-year net loss. Offsetting these positives are the end of legacy revenue, the Q4 profit being driven by a one-time non-cash gain rather than recurring operations, slow enrollment risk for the rare PCNSL population, and contingent financing tied to clinical milestones. On balance the updates reflect solid clinical progress and a strengthened near-term financial position, but with key operational and revenue risks that investors should monitor.Company Guidance
Registrational Pathway for PCNSL with Regulatory Support
TakeAim Lymphoma (PCNSL) is a single-arm registrational study with an ORR endpoint; company reports collaborative discussions with FDA and EMA and expects the study to support accelerated submissions in the US and Europe. Enrollment is on track with an estimated 12–18 months to full enrollment and potential filing in 2027 after ~6 months of follow-up.
Encouraging AML Triplet Data (MRD Conversion)
At ASH, Curis presented early data from the AML triplet study (emavusertib + azacitidine + venetoclax): 5 of 8 evaluable patients achieved MRD conversion (62.5%), described as encouraging initial efficacy signal.
Progress into CLL with Proof-of-Concept Study
Company has initiated site activations in the US and Europe for a proof-of-concept study adding emavusertib to BTKi in CLL to deepen responses (aiming for CR/MRD negativity). Initial data are anticipated for the ASH Annual Meeting in December 2026.
Improved FY2025 Financial Result vs. FY2024
Full-year net loss narrowed to $7.6M in 2025 from $43.4M in 2024, an improvement of $35.8M (≈82.6% reduction in net loss year-over-year).
Q4 2025 Net Income Driven by One-Time Gain
Curis reported Q4 2025 net income of $19.4M ($1.23 per share) versus a Q4 2024 net loss of $9.6M; the Q4 2025 result reflects a $27.2M one-time non-cash gain from the sale of Erivedge to Oberland.
Lower Operating Expenses and Strengthened Cash Position
R&D and G&A costs declined: Q4 R&D down to $5.8M from $9.0M (≈35.6% decrease); full-year R&D down to $28.3M from $38.6M (≈26.7% decrease). Q4 G&A down to $2.9M from $3.4M (≈14.7% decrease); full-year G&A down to $14.0M from $16.8M (≈16.7% decrease). Cash and cash equivalents as of 12/31/2025 plus $20.2M received in Jan 2026 and up to an additional $20.2M from warrant exercise (contingent) are expected to fund planned operations into 2027.
CRIS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CRIS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 19, 2026 | $0.76 | $0.77 | +1.98% |
Nov 06, 2025 | $1.42 | $1.46 | +2.82% |
Aug 05, 2025 | $1.60 | $1.67 | +4.37% |
May 06, 2025 | $2.45 | $2.19 | -10.61% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Curis Inc (CRIS) report earnings?
Curis Inc (CRIS) is schdueled to report earning on May 12, 2026, Before Open (Confirmed).
What is Curis Inc (CRIS) earnings time?
Curis Inc (CRIS) earnings time is at May 12, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CRIS EPS forecast?
CRIS EPS forecast for the fiscal quarter 2026 (Q1) is -0.29.